PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer

The aim of this study was to explore the efficacy of mTOR inhibitor for castration-resistant prostate cancer (CRPC) under hypoxia. Although under normoxia C4-2AT6, it is a CRPC cell line, expressed elevated pAkt, pS6 and Pyruvate kinase M2 (PKM2) accompanied by elevated HIF-1a expression, 5% hypoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasumizu, Yota, Hongo, Hiroshi, Kosaka, Takeo, Mikami, Shuji, Nishimoto, Koshiro, Kikuchi, Eiji, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021245/
https://www.ncbi.nlm.nih.gov/pubmed/29963230
http://dx.doi.org/10.18632/oncotarget.25498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021245/
https://www.ncbi.nlm.nih.gov/pubmed/29963230
http://dx.doi.org/10.18632/oncotarget.25498

Ejemplares similares